Street Calls of the Week
Cathie Wood’s ARK ETFs have once again made notable adjustments to their portfolios, as revealed in their daily trade report for Tuesday, February 4th, 2025. The most significant move was the sale of Palantir Technologies Inc (NYSE:NASDAQ:PLTR) shares, which amounted to a staggering $5,951,317. This action marks a continued trend of ARK reducing its position in the data analytics firm.
On the purchasing side, ARK displayed a bullish stance on 10X Genomics Inc (NASDAQ:TXG), investing an additional $1,726,760 into the genomics company. This follows a pattern of consistent buying in recent days, signaling a strong conviction in the stock’s future performance.
The daily trade report also highlighted ARK’s increased investment in Illumina Inc (NASDAQ:ILMN), with a total of 63,407 shares acquired across the ARKK and ARKG ETFs. This move could be indicative of ARK’s confidence in the biotechnology sector and Illumina’s role within it.
Additionally, ARK bought shares of Twist Bioscience Corp (NASDAQ:TWST) valued at $1,141,932, and L3Harris Technologies Inc (NYSE:LHX) with a total investment of $448,327, reflecting a diverse interest in both the biotech and technology sectors.
On the sell side, apart from the notable reduction of Palantir shares, ARK sold 198,395 shares of Accolade Inc (NASDAQ:ACCD) through its ARKG ETF, totaling $1,376,861. This continues a selling trend observed over the past week for Accolade Inc.
Other smaller trades included selling positions in Adyen (AS:ADYEN) NV (OTC:ADYEY), Lockheed Martin Corp (NYSE:LMT), and Nu Holdings Ltd (NYSE:NU), with the latter being a consistent sell in ARK’s recent trading history.
Investors following Cathie Wood’s ARK ETFs should note these transactions as part of a broader strategy, which seems to focus on genomic innovation and cutting-edge technology, while reducing exposure to certain companies like Palantir Technologies and Accolade Inc. As always, these daily trade reports provide a window into the active management style that has become synonymous with ARK’s investment approach.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.